V
Velarion™Intelligence
Sign InFree TrialBook a Walkthrough
Biopharma & Life Sciences

OPKO Health Executive Compensation (FY25)

OPK · Executive and director compensation, fiscal 2023 to 2025
Data as of September 7, 2026Latest filing (8-K): June 18, 2026
193 figures on this page: 183 cited to the filing that reported them, 10 calculated from figures it prints. See the citations
Total compensation for Phillip Frost, Chief Executive Officer, came to $1,854,000 in fiscal 2025, and Frost's total moved 14.3% lower from the $2,163,800 reported for fiscal 2024. The company reported a chief executive pay ratio of 42:1 for fiscal 2025, against median employee compensation of $44,252. Separately, for fiscal 2025, shareholders backed the say-on-pay proposal with 96.2% of votes cast for or against in favor at the meeting held June 18, 2026. For fiscal 2025, the company reported 5 named executive officers.
Chief executive, fiscal 2025
◇
Phillip Frost
Latest say-on-pay support
=
June 18, 2026
Chief executive pay ratio
◇
To the median employee
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Phillip Frost: $2,163,800 → $1,854,000 (14.3% lower)
Say-on-pay support: 97.6% → 96.2% (1.4 points lower)
CEO pay ratio: 47:1 → 42:1 (10.6% lower)

Frequently asked questions

Answers drawn from the data on this page.
Who is OPKO Health's chief executive and what were they paid?
Total compensation for Phillip Frost, Chief Executive Officer, came to $1,854,000 in fiscal 2025. Frost's total moved 14.3% lower from the $2,163,800 reported for fiscal 2024.
What was OPKO Health's say-on-pay result?
For fiscal 2025, shareholders backed the say-on-pay proposal with 96.2% of votes cast for or against in favor at the meeting held June 18, 2026.
What is OPKO Health's chief executive pay ratio?
The company reported a chief executive pay ratio of 42:1 for fiscal 2025, against median employee compensation of $44,252.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Phillip Frost
Chief Executive Officer
◇◇—◇——◇◇
Elias Zerhouni
Vice Chairman and President
◇◇—◇——◇◇
Jane Hsiao
Vice-Chairman and Chief Technical Officer
◇◇—◇——◇◇
Steven Rubin
Executive Vice President – Administration
◇◇—◇——◇◇
Adam Logal
Senior Vice President, Chief Financial Officer, Chief Accounting Officer, and Treasurer
◇◇—◇——◇◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Phillip Frost
Chief Executive Officer
◇◇◇———◇◇
Jane Hsiao
Vice-Chairman and Chief Technical Officer
◇◇◇———◇◇
Elias Zerhouni
Vice Chairman and President
◇◇◇———◇◇
Steven Rubin
Executive Vice President – Administration
◇◇◇———◇◇
Adam Logal
Senior Vice President, Chief Financial Officer, Chief Accounting Officer, and Treasurer
◇◇◇———◇◇
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Phillip Frost
Chief Executive Officer
◇◇—◇——◇◇
Elias Zerhouni
Vice Chairman and President
◇◇—◇——◇◇
Jane Hsiao
Vice-Chairman and Chief Technical Officer
◇◇—◇——◇◇
Steven Rubin
Executive Vice President – Administration
◇◇—◇——◇◇
Adam Logal
Senior Vice President, Chief Financial Officer, Chief Accounting Officer, and Treasurer
◇◇—◇——◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
Adam LogalOPTION◇——◇—◇◇
Elias A. ZerhouniOPTION◇——◇—◇◇
Jane H. HsiaoOPTION◇——◇—◇◇
Phillip FrostOPTION◇——◇—◇◇
Steven D. RubinOPTION◇——◇—◇◇
Fiscal 2023, 2024 are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Adam LogalOption◇—◇—
Option◇—◇—
RSU◇◇——
Steven RubinOption◇—◇—
Option◇—◇—
RSU◇◇——
Elias ZerhouniOption◇—◇—
Option◇—◇—
RSU◇◇——
Jane HsiaoOption◇—◇—
Option◇—◇—
Phillip FrostOption◇—◇—
Option◇—◇—
Option◇—◇—
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director compensation

What each non-employee director was paid.
Fiscal 2025
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Richard C. Pfenniger Jr
Lead independent director
◇◇————◇
Richard C. Pfenniger, Jr
Lead independent director
◇—◇———◇
Prem A. Lachman, M.D
◇◇————◇
Richard M. Krasno, Ph.D
◇◇————◇
John A. Paganelli
◇◇————◇
Roger J. Medel, M.D
◇◇————◇
Alice Lin-Tsing Yu, M.D., Ph.D
◇◇————◇
Jane H. Hsiao, Ph.D., MBA, Elias A. Zerhouni, M.D, Gary J. Nabel, M.D., Ph.D, Phillip Frost, M.D, Steven D. Rubin and Subbarao V. Uppaluri, Ph.D served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Total board retainer◇
Board chair premium◇
Lead independent director premium◇
Audit committee member◇
Compensation committee member◇
Equity is delivered as Options.

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2025June 18, 2026=◇◇◇
2024April 23, 2025=◇◇◇
2023March 28, 2024=◇◇◇
2022June 22, 2023=◇◇◇
2021July 14, 2022=◇◇◇
2020June 24, 2021=◇◇◇
2019June 25, 2020=◇◇◇
2018June 20, 2019=◇◇◇
2017June 21, 2018=◇◇◇
2016June 15, 2017=◇◇◇

Chief executive pay ratio

As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇
Email me this page as a cited PDF
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.
Tell me when OPKO Health files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact OPKO Health disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $1,200
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Enquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for a Velarion Pro seat
Full platform access for one person: every industry we cover, peer positioning, and the written analysis. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.
Join the list for Peer Group Review
Whether OPKO Health's disclosed peer group is defensible, who names OPKO Health back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
193 figures on this page: 183 cited to the filing that reported them, 10 calculated from figures it prints.
183 cited to the filing
10 calculated from the filing

Documents cited

  1. 0001193125-26-275818
  2. 0001437749-25-007736
    Summary Compensation Table · Summary Compensation Table for 2022-2024
  3. 0001193125-26-197120
    EXECUTIVE COMPENSATION · Fiscal 2025 Director Compensation · Summary Compensation Table for 2023
  4. 0001437749-25-012806
  5. 0001437749-24-010069
  6. 0001437749-24-006106
    Summary Compensation Table for 2021 - 2023
  7. 0001437749-23-018259
  8. 0000944809-22-000035
  9. 0000944809-21-000044
  10. 0000944809-20-000022
  11. 0000944809-19-000041
  12. 0000944809-18-000029
  13. 0001193125-17-204730
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “OPKO Health executive compensation, FY2023–FY2025.” https://intel.velarion.ai/comp/OPK (accessed 2026).
Short form: data: Velarion
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about OPKO Health and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Biopharma & Life Sciences rankings

Chief executive pay — Biopharma & Life SciencesCEO pay ratio — Biopharma & Life SciencesSay-on-pay support — Biopharma & Life Sciences

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  The Pay Desk · Methodology · Terms · Privacy